Rui Cao

Rui Cao

Auto-generated profile, based on publicly available information

Rui Cao

Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2019 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
RCRui Cao
Rui Cao
LYLushun Yuan
Lushun Yuan
BMBo Ma
Bo Ma
GWGang Wang
Gang Wang
WQWei Qiu
Wei Qiu
YTYe Tian
Ye Tian
The transition from non–muscle‐invasive bladder cancer (NMIBC) to muscle‐invasive bladder cancer (MIBC) is detrimental to bladder cancer (BLCA) patients. Here, we aimed to study the underlying mechanism of the subtype transition. Gene set variation analysis (GSVA) revealed the epithelial‐mesenchymal transition (EMT) signalling pathway with the most positive correlation in this transition. Then, we built a LASSO Cox regression model of an EMT‐related gene signature in BLCA. The patients with high risk scores had significantly worse overall survival (OS) and disease‐free survival (DFS) than those with low risk scores. The EMT‐related gene signature also performed favourably in the accuracy of prognosis and in the subtype survival analysis. Univariate and multivariate Cox regression analyses demonstrated that the EMT‐related gene signature, pathological N stage and age were independent prognostic factors for predicting survival in BLCA patients. Furthermore, the predictive nomogram model was able to effectively predict the outcome of BLCA patients by appropriately stratifying the risk score. In conclusion, we developed a novel EMT‐related gene signature that has tumour‐promoting effects, acts as a negative independent prognostic factor and might facilitate personalized counselling and treatment in BLCA.

2 July 2020 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
RCRui Cao
Rui Cao
LYLushun Yuan
Lushun Yuan
BMBo Ma
Bo Ma
GWGang Wang
Gang Wang
YTYe Tian
Ye Tian

19 April 2011 in Journal of Proteome Research
Verified
Journal Article
Closed access
JCJing Chen
Jing Chen
XZXiaoyan Zhang
Xiaoyan Zhang
RCRui Cao
Rui Cao
XLXin Lu
Xin Lu
SZSumin Zhao
Sumin Zhao
Guowang XuGuowang Xu
Guowang Xu

20 September 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
RCRui Cao
Rui Cao
ZMZhe Meng
Zhe Meng
TLTong-Zu Liu
Tong-Zu Liu
GWGang Wang
Gang Wang
GQGuofeng Qian
Guofeng Qian
XWXinghuan Wang
Xinghuan Wang
Decreased TRPM7 inhibits activities and induces apoptosis of bladder cancer cells via ERK1/2 pathway

27 November 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
TLTao Liu
Tao Liu
WXWan Xiang
Wan Xiang
ZCZhizhuang Chen
Zhizhuang Chen
GWGang Wang
Gang Wang
RCRui Cao
Rui Cao
LCLiang Chen
Liang Chen
Clear cell renal cell carcinoma (ccRCC) is a type of kidney cancer that is both common and aggressive, with a rising incidence in recent decades. Hypoxia is a key factor that plays a vital role in the tumorigenesis and metastasis of malignancy. However, the precise mechanisms of hypoxia driving ccRCC progression were not totally uncovered. Our study found that hypoxia level was elevated in ccRCC and might be an independent risk factor of prognosis in ccRCC patients. We identified a key protein PLOD2 was induced under hypoxic conditions and strongly associated with poor prognosis in ccRCC patients. When PLOD2 was depleted, the proliferation and migration of ccRCC cells were reduced in vitro and in vivo, while overexpression of PLOD2 had the opposite effect. Mechanically, the study further revealed that PLOD2 was transcriptionally activated by HIF1A, which binds to a specific promoter region of the PLOD2 gene. PLOD2 was also shown to interact with EGFR, leading to the phosphorylation of the receptor. Furthermore, PLOD2 was responsible for binding to the extracellular domain of EGFR, which ultimately activated the AKT signaling pathway, thus promoting the malignant progression of ccRCC. Treatment with the PLOD2 inhibitor Minoxidil significantly suppressed ccRCC progression by inactivating the EGFR/AKT signaling axis. In summary, the findings of this study shed light on the molecular mechanisms behind PLOD2 expression in ccRCC and suggest that it may serve as a potential predictor and therapeutic target for the clinical prognosis and treatment of ccRCC.